Erfonrilimab (Anti-CTLA4 & PD-L1)
Product Specifications
CAS Number
2367013-69-0
Synonyms
KN 046
SKU
C00871-1mg
Target
PD-1/PD-L1
Applications
Apoptosis
Additionnal Information
Erfonrilimab is a humanized bispecific monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. It is used to treat solid tumors and exhibits promising efficacy in advanced non-small cell lung cancer (NSCLC) patients who had experienced failure or intolerance to prior platinum-based chemotherapy. MW: 107.44 KD.
Storage Conditions
-80°C (avoid freeze-thaw cycles)
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC880630-100 1x 100 µL
Mucin 1 / EMA / Episialin / CD227 (VU-2G7), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC740149-100 1x 100 µL
CD106 / VCAM1 (1.4C3), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC050391-100 1x 100 µL
CD81 / TAPA-1 (1.3.3.22), CF405M conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC401003-500 1x 500 µL
Mucin 5AC (MUC5AC) (58M1), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details